RenovoRx, Inc. RNXT
1.24 USD +0.06 (+5.08%)
Nov 11, 2026, 2:00 PM EST
1.12 Day range 1.26
0.701 52-week range 2.59
- YTD
- +47.62%
- 1 year
- +15.89%
Benzinga news
benzinga.com CORRECTION: RenovoRx Q3 Adj. EPS $(0.07) Misses $(0.06) Estimate, Sales $1.066M Beat $1.065M Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year. The…
benzinga.com RenovoRx Q3 2026 Earnings Call Transcript RenovoRx (NASDAQ:RNXT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com RenovoRx Affirms FY2026 Sales Guidance of $3.750M-$4.250M vs $3.873M Est RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.750 million-$4.250 million to $3.750 million-$4.250 million vs $3.873 million estimate.
benzinga.com RenovoRx Q3 Adj. EPS $(0.08) Misses $(0.06) Estimate, Sales $1.066M Beat $1.065M Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is unchanged from the same period last year. The…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs…
benzinga.com RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
benzinga.com RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
benzinga.com Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5 Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2…
benzinga.com RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared- benzinga.com RenovoRx Says USPTO Issues Notice Of Allowance For Patent Application Titled Methods And Apparatuses For Delivery Of Therapeutic Materials For The Treatment Of Cancer RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…- benzinga.com RenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M Est RenovoRx (NASDAQ:RNXT) raises FY2026 sales outlook from $3.000 million-$4.000 million to $3.750 million-$4.250 million vs $3.203 million estimate.
- benzinga.com RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.08) per…
benzinga.com EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecting topline data in H2 2027.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press…
benzinga.com Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.
benzinga.com Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14 Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13.5 to $14.
benzinga.com RenovoRx Announces FDA Orphan Drug Designation Of Oxaliplatin For The Treatment Of Pancreatic Cancer The designation was issued by the FDA's Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Oxaliplatin is an approved and…- benzinga.com RenovoRx Announces Online Publication Of Abstract From Pharmacokinetic And Pharmacodynamic Sub-Study Of Ongoing Phase III TIGeR-PaC Clinical Trial In Connection With 2026 ASCO Annual Meeting Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic…
- benzinga.com RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript
- benzinga.com RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est. RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 million-$4.000 million vs $3.244 million estimate.
- benzinga.com RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate. RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period…
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13.5 Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13 to $13.5.- benzinga.com HC Wainwright & Co. Reiterates Buy on RenovoRx, Maintains $3 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates RenovoRx (NASDAQ:RNXT) with a Buy and maintains $3 price target.
- benzinga.com RenovoRx Secures Notice Of Allowance From Japan Patent Office For Application Titled "Method and Apparatus for Delivering an Agent Through the Vasa Vasorum" The allowed claims of the patent protect the RenovoCath dual-occlusion catheter-based system equipped with integrated imaging and pressure-sensing technology that is designed to enable targeted…
- benzinga.com RenovoRx Q4 EPS $(0.08), Inline, Sales $238.000K Miss $419.750K Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.12) per share from the same period…
- benzinga.com Earnings Scheduled For March 30, 2026
- benzinga.com RenovoRx Announces $10M At-The-Market Private Placement For Oversubscribed Common Stock And Milestone Warrant Private Placement The proceeds from this financing are expected to allow RenovoRx to capitalize on and accelerate its commercialization efforts for RenovoCath® in 2026 as the Company seeks to increase revenue, reduce…
- benzinga.com RenovoRx Announces 12 U.S. Centers Using Its RenovoCath Device RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared…
benzinga.com Micron To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Tuesday - benzinga.com Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13 Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $12.5 to $13.
- benzinga.com RenovoRx Creates RenovoCath Medical Advisory Board For Its Clinical, Strategic Initiatives RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared…
- benzinga.com RenovoRx Appoints Mark Voll CFO, Effective Feb. 1 RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared…
- benzinga.com RenovoRx To Present New Clinical Data At 2026 Society Of Interventional Oncology Annual Scientific Meeting On Feb. 6 RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared…
- benzinga.com RenovoRx's Abstract Submission Accepted RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - benzinga.com RenovoRx To Present New Clinical Data Abstract From PK And Pharmacodynamic Sub‑Study Of Ongoing Phase III TIGeR‑PaC Clinical Trial At 2026 ASCO GI New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx's TAMP Therapy Platform as a Targeted Drug-Delivery ApproachData Shows a…
benzinga.com Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com RenovoRx Q3 EPS $(0.08), Inline, Sales $266.000K Miss $405.333K Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period…
- benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com RenovoRx Completes First Registry-Eligible Patient Procedure In PanTheR Post-Marketing Registry Study At University Of Vermont Cancer Center First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer CenterBaptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of…
benzinga.com Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com RenovoRx Announces The Independent Data Monitoring Committee For Its Ongoing Phase III TIGeR-PaC Trial Has Recommended To Continue The Study "At the same time, we are very excited to report that the independent Data Monitoring Committee (DMC) for our ongoing Phase III TIGeR-PaC trial recently completed their review of our second…